Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum
Neurofilament light chain (NfL) is a potential diagnostic and prognostic plasma biomarker for numerous neurological diseases including Alzheimer’s disease (AD). In this study, we investigated the relationship between baseline plasma concentration of Nfl and Mild Cognitive Impairment in participants...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/24/17361 |
| _version_ | 1797380758830055424 |
|---|---|
| author | Sylvain Lehmann Susanna Schraen-Maschke Jean-Sébastien Vidal Frédéric Blanc Claire Paquet Bernadette Allinquant Stéphanie Bombois Audrey Gabelle Constance Delaby Olivier Hanon |
| author_facet | Sylvain Lehmann Susanna Schraen-Maschke Jean-Sébastien Vidal Frédéric Blanc Claire Paquet Bernadette Allinquant Stéphanie Bombois Audrey Gabelle Constance Delaby Olivier Hanon |
| author_sort | Sylvain Lehmann |
| collection | DOAJ |
| description | Neurofilament light chain (NfL) is a potential diagnostic and prognostic plasma biomarker for numerous neurological diseases including Alzheimer’s disease (AD). In this study, we investigated the relationship between baseline plasma concentration of Nfl and Mild Cognitive Impairment in participants who did and did not have a clinically determined diagnosis of dementia by the end of the three-year study. Additionally, we explored the connection between baseline plasma concentration of NfL and AD dementia patients, considering their demographics, clinical features, and cognitive profiles. A total of 350 participants from the Biomarker of AmyLoid pepTide and AlZheimer’s diseAse Risk (BALTAZAR) multicenter prospective study were investigated: 161 AD dementia participants and 189 MCI participants (of which 141 had amnestic MCI and 48 non-amnestic MCI). Plasma biomarkers were measured at baseline and the progression of clinical and cognitive profiles was followed over the three years of follow-up. Baseline plasma NfL concentration increased across the Alzheimer’s disease continuum with a mean NfL value of 17.1 ng/mL [SD = 6.1] in non-amnestic MCI, 20.7 ng/mL [SD = 12.0] in amnestic MCI, and 23.1 ng/mL [SD = 22.7] in AD dementia patients. Plasma NfL concentration correlated with age, body mass index (BMI), and global cognitive performance and decline, as measured by the Mini-Mental State Examination (MMSE). MMSE scores decreased in parallel with increasing plasma NfL concentration, independently of age and BMI. However, NfL concentration did not predict MCI participants’ conversion to dementia within three years. Discussion: Baseline plasma NfL concentration is associated with cognitive status along the AD continuum, suggesting its usefulness as a potential informative biomarker for cognitive decline follow-up in patients. |
| first_indexed | 2024-03-08T20:41:42Z |
| format | Article |
| id | doaj.art-4ce3401c0d724e1cb1267cc43c99cc66 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-08T20:41:42Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-4ce3401c0d724e1cb1267cc43c99cc662023-12-22T14:14:11ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-12-0124241736110.3390/ijms242417361Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease ContinuumSylvain Lehmann0Susanna Schraen-Maschke1Jean-Sébastien Vidal2Frédéric Blanc3Claire Paquet4Bernadette Allinquant5Stéphanie Bombois6Audrey Gabelle7Constance Delaby8Olivier Hanon9Laboratoire et Plateforme de Protéomique Clinique, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, 80 av Fliche, F-34295 Montpellier, FranceUniv. Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, F-59000 Lille, FranceUniversité Paris Cité, INSERM U1144, GHU APHP Centre, Hopital Broca, Memory Resource and Research Centre de Paris-Broca-Ile de France, F-75013 Paris, FranceUniversité de Strasbourg, Hôpitaux Universitaires de Strasbourg, Memory Resource and Research, French National Centre for Scientific Research (CNRS), ICube Laboratory UMR7357 and Fédération de Médecine Translationnelle de Strasbourg (FMTS), Team Imagerie Multimodale Intégrative en Santé (IMIS), F-67000 Strasbourg, FranceUniversité Paris Cité, INSERM U1144, GHU APHP Nord Lariboisière Fernand Widal, Centre de Neurologie Cognitive, F-75010 Paris, FranceUniversité Paris Cité, Institute of Psychiatry and Neurosciences, Inserm, UMR-S 1266, F-75014 Paris, FranceUniv. Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, F-59000 Lille, FranceUniversité de Montpellier, CHU Montpellier, Memory Research and Resources Center, Department of Neurology, Inserm INM NeuroPEPs Team, Excellence Center of Neurodegenerative Disorders, F-34000 Montpellier, FranceLaboratoire et Plateforme de Protéomique Clinique, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, 80 av Fliche, F-34295 Montpellier, FranceUniversité Paris Cité, INSERM U1144, GHU APHP Centre, Hopital Broca, Memory Resource and Research Centre de Paris-Broca-Ile de France, F-75013 Paris, FranceNeurofilament light chain (NfL) is a potential diagnostic and prognostic plasma biomarker for numerous neurological diseases including Alzheimer’s disease (AD). In this study, we investigated the relationship between baseline plasma concentration of Nfl and Mild Cognitive Impairment in participants who did and did not have a clinically determined diagnosis of dementia by the end of the three-year study. Additionally, we explored the connection between baseline plasma concentration of NfL and AD dementia patients, considering their demographics, clinical features, and cognitive profiles. A total of 350 participants from the Biomarker of AmyLoid pepTide and AlZheimer’s diseAse Risk (BALTAZAR) multicenter prospective study were investigated: 161 AD dementia participants and 189 MCI participants (of which 141 had amnestic MCI and 48 non-amnestic MCI). Plasma biomarkers were measured at baseline and the progression of clinical and cognitive profiles was followed over the three years of follow-up. Baseline plasma NfL concentration increased across the Alzheimer’s disease continuum with a mean NfL value of 17.1 ng/mL [SD = 6.1] in non-amnestic MCI, 20.7 ng/mL [SD = 12.0] in amnestic MCI, and 23.1 ng/mL [SD = 22.7] in AD dementia patients. Plasma NfL concentration correlated with age, body mass index (BMI), and global cognitive performance and decline, as measured by the Mini-Mental State Examination (MMSE). MMSE scores decreased in parallel with increasing plasma NfL concentration, independently of age and BMI. However, NfL concentration did not predict MCI participants’ conversion to dementia within three years. Discussion: Baseline plasma NfL concentration is associated with cognitive status along the AD continuum, suggesting its usefulness as a potential informative biomarker for cognitive decline follow-up in patients.https://www.mdpi.com/1422-0067/24/24/17361Alzheimer’s diseaseneurofilament light chainbloodcognitive decline |
| spellingShingle | Sylvain Lehmann Susanna Schraen-Maschke Jean-Sébastien Vidal Frédéric Blanc Claire Paquet Bernadette Allinquant Stéphanie Bombois Audrey Gabelle Constance Delaby Olivier Hanon Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum International Journal of Molecular Sciences Alzheimer’s disease neurofilament light chain blood cognitive decline |
| title | Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum |
| title_full | Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum |
| title_fullStr | Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum |
| title_full_unstemmed | Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum |
| title_short | Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum |
| title_sort | blood neurofilament levels predict cognitive decline across the alzheimer s disease continuum |
| topic | Alzheimer’s disease neurofilament light chain blood cognitive decline |
| url | https://www.mdpi.com/1422-0067/24/24/17361 |
| work_keys_str_mv | AT sylvainlehmann bloodneurofilamentlevelspredictcognitivedeclineacrossthealzheimersdiseasecontinuum AT susannaschraenmaschke bloodneurofilamentlevelspredictcognitivedeclineacrossthealzheimersdiseasecontinuum AT jeansebastienvidal bloodneurofilamentlevelspredictcognitivedeclineacrossthealzheimersdiseasecontinuum AT fredericblanc bloodneurofilamentlevelspredictcognitivedeclineacrossthealzheimersdiseasecontinuum AT clairepaquet bloodneurofilamentlevelspredictcognitivedeclineacrossthealzheimersdiseasecontinuum AT bernadetteallinquant bloodneurofilamentlevelspredictcognitivedeclineacrossthealzheimersdiseasecontinuum AT stephaniebombois bloodneurofilamentlevelspredictcognitivedeclineacrossthealzheimersdiseasecontinuum AT audreygabelle bloodneurofilamentlevelspredictcognitivedeclineacrossthealzheimersdiseasecontinuum AT constancedelaby bloodneurofilamentlevelspredictcognitivedeclineacrossthealzheimersdiseasecontinuum AT olivierhanon bloodneurofilamentlevelspredictcognitivedeclineacrossthealzheimersdiseasecontinuum |